Alzforum

Alzforum company information, Employees & Contact Information

Explore related pages

Related company profiles:

Alzforum, founded in 1996, is a free, dynamic, web-based scientific community dedicated to understanding Alzheimer's disease and related disorders. Our editorial priorities are as diverse as the needs of the research community. The website reports news on the latest scientific findings from basic research to clinical trials; maintains public databases of animal models, therapeutics, genetic risk factors, and biomarkers; and holds live discussion forums to promote debate, speed the dissemination of new ideas, and break down barriers across the numerous disciplines that can contribute to the global effort to cure Alzheimer's disease. The Alzforum team of professional science writers and editors, information technology experts, Web developers, and producers all work with our distinguished Advisory Board to ensure a high quality of information and services. We welcome our readers' participation in all aspects of the website. Alzforum is developed and operated by FBRI LLC. FBRI is a wholly owned subsidiary of FMR LLC. FMR LLC and its affiliates invest broadly in many companies, including life sciences and pharmaceutical companies. The Alzforum website does not endorse any specific product or scientific approach.

Company Details

Employees
16
Founded
-
Address
1 Main Street, Suite 13, Cambridge,ma 02142,united States
Email
co****@****rum.org
Industry
Information Services
NAICS
Other Information Services
News Syndicates
All Other Information Services
Keywords
Cambridge.
HQ
Cambridge, MA
Looking for a particular Alzforum employee's phone or email?

Alzforum Questions

News

Immune modulation to treat Alzheimer’s disease - Molecular Neurodegeneration

Immune modulation to treat Alzheimer’s disease Molecular Neurodegeneration

Newer Therapeutic Approaches in Treating Alzheimer’s Disease: A Comprehensive Review - ACS Publications

Newer Therapeutic Approaches in Treating Alzheimer’s Disease: A Comprehensive Review ACS Publications

The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease - Frontiers

The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease Frontiers

Passive immunotherapies targeting Aβ and tau in Alzheimer's disease - ScienceDirect.com

Passive immunotherapies targeting Aβ and tau in Alzheimer's disease ScienceDirect.com

In vivo hyperphosphorylation of tau is associated with synaptic loss and behavioral abnormalities in the absence of tau seeds - Nature

In vivo hyperphosphorylation of tau is associated with synaptic loss and behavioral abnormalities in the absence of tau seeds Nature

Amyloid Imaging–Based Food and Drug Administration Approval of Lecanemab to Treat Alzheimer Disease—What Lasts Long Finally Becomes Good? - Journal of Nuclear Medicine

Amyloid Imaging–Based Food and Drug Administration Approval of Lecanemab to Treat Alzheimer Disease—What Lasts Long Finally Becomes Good? Journal of Nuclear Medicine

Common genetic variation within the Low-Density Lipoprotein Receptor-Related Protein 6 and late-onset Alzheimer's disease - PNAS

Common genetic variation within the Low-Density Lipoprotein Receptor-Related Protein 6 and late-onset Alzheimer's disease PNAS

A new way APP mismetabolism can lead to Alzheimer's disease - EMBO Press

A new way APP mismetabolism can lead to Alzheimer's disease EMBO Press

Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease - Frontiers

Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease Frontiers

Alzheimer culprits: Cellular crossroads and interplay - ScienceDirect.com

Alzheimer culprits: Cellular crossroads and interplay ScienceDirect.com

Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China - Frontiers

Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China Frontiers

Aducanumab for Alzheimer’s disease: A regulatory perspective - ScienceDirect.com

Aducanumab for Alzheimer’s disease: A regulatory perspective ScienceDirect.com

Clinical characteristics and genotype-phenotype correlation analysis of familial Alzheimer’s disease patients with pathogenic/likely pathogenic amyloid protein precursor mutations - Frontiers

Clinical characteristics and genotype-phenotype correlation analysis of familial Alzheimer’s disease patients with pathogenic/likely pathogenic amyloid protein precursor mutations Frontiers

New Insights Into Drug Discovery Targeting Tau Protein - Frontiers

New Insights Into Drug Discovery Targeting Tau Protein Frontiers

Emerging Alzheimer’s disease therapeutics: promising insights from lipid metabolism and microglia-focused interventions - Frontiers

Emerging Alzheimer’s disease therapeutics: promising insights from lipid metabolism and microglia-focused interventions Frontiers

β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease - Frontiers

β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease Frontiers

Immunotherapies for Neurodegenerative Diseases - Frontiers

Immunotherapies for Neurodegenerative Diseases Frontiers

Pain Research Forum: application of scientific social media frameworks in neuroscience - Frontiers

Pain Research Forum: application of scientific social media frameworks in neuroscience Frontiers

The future is precision medicine-guided diagnoses, preventions and treatments for neurodegenerative diseases - Frontiers

The future is precision medicine-guided diagnoses, preventions and treatments for neurodegenerative diseases Frontiers

Investigation of the role of miRNA variants in neurodegenerative brain diseases - Frontiers

Investigation of the role of miRNA variants in neurodegenerative brain diseases Frontiers

Mouse Models of Alzheimer’s Disease - Frontiers

Mouse Models of Alzheimer’s Disease Frontiers

Novel Therapies for Parkinsonian Syndromes–Recent Progress and Future Perspectives - Frontiers

Novel Therapies for Parkinsonian Syndromes–Recent Progress and Future Perspectives Frontiers

Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer’s disease with reduced complement activation - Nature

Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer’s disease with reduced complement activation Nature

PSEN1 c.1292C A Variant and Early-Onset Alzheimer’s Disease: A Scoping Review - Frontiers

PSEN1 c.1292C A Variant and Early-Onset Alzheimer’s Disease: A Scoping Review Frontiers

Association of naturally occurring antibodies to β-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer’s disease - Science | AAAS

Association of naturally occurring antibodies to β-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer’s disease Science | AAAS

Genetic analyses of early-onset Alzheimer’s disease using next generation sequencing - Nature

Genetic analyses of early-onset Alzheimer’s disease using next generation sequencing Nature

Single-cell-led drug repurposing for Alzheimer’s disease - Nature

Single-cell-led drug repurposing for Alzheimer’s disease Nature

Late-onset vs nonmendelian early-onset Alzheimer disease - Neurology® Journals

Late-onset vs nonmendelian early-onset Alzheimer disease Neurology® Journals

APP PSEN1 , and PSEN2 Variants in Alzheimer’s Disease: Systematic Re-evaluation According to ACMG Guidelines - Frontiers

APP PSEN1 , and PSEN2 Variants in Alzheimer’s Disease: Systematic Re-evaluation According to ACMG Guidelines Frontiers

Amyloid-β1–43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations - Alzheimer's Research & Therapy

Amyloid-β1–43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations Alzheimer's Research & Therapy

Would UK approval of lecanemab be a game changer for people with Alzheimer’s disease? - The Pharmaceutical Journal

Would UK approval of lecanemab be a game changer for people with Alzheimer’s disease? The Pharmaceutical Journal

Identification and Clinical Analysis of the First Nonsense Mutation in the PSEN1 Gene in a Family With Acute Encephalopathy and Retinitis Pigmentosa - Frontiers

Identification and Clinical Analysis of the First Nonsense Mutation in the PSEN1 Gene in a Family With Acute Encephalopathy and Retinitis Pigmentosa Frontiers

3 Incredible Breakthroughs That Are Transforming Our Understanding of the Brain - Prevention

3 Incredible Breakthroughs That Are Transforming Our Understanding of the Brain Prevention

Quaternary Structure Defines a Large Class of Amyloid-β Oligomers Neutralized by Sequestration - ScienceDirect.com

Quaternary Structure Defines a Large Class of Amyloid-β Oligomers Neutralized by Sequestration ScienceDirect.com

Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases - Journal of Neuroinflammation

Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases Journal of Neuroinflammation

Remembering John Q Trojanowski, in his own words: A life dedicated to discovering building blocks and using them to build bridges of knowledge, collaboration, and discovery | npj Parkinson's Disease - Nature

Remembering John Q Trojanowski, in his own words: A life dedicated to discovering building blocks and using them to build bridges of knowledge, collaboration, and discovery | npj Parkinson's Disease Nature

The Rhesus Macaque as a Translational Model for Neurodegeneration and Alzheimer’s Disease - Frontiers

The Rhesus Macaque as a Translational Model for Neurodegeneration and Alzheimer’s Disease Frontiers

“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies - Molecular Neurodegeneration

“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies Molecular Neurodegeneration

Hope for Dementia-Related Psychosis - Psychiatric Times

Hope for Dementia-Related Psychosis Psychiatric Times

Modeling the β-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer’s disease - Molecular Neurodegeneration

Modeling the β-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer’s disease Molecular Neurodegeneration

Role of genes linked to sporadic Alzheimer’s disease risk in the production of β-amyloid peptides - PNAS

Role of genes linked to sporadic Alzheimer’s disease risk in the production of β-amyloid peptides PNAS

How one woman became the exception to her family’s Alzheimer’s history - Science News

How one woman became the exception to her family’s Alzheimer’s history Science News

Memory-Enhancing Supplements: What’s the Evidence? - Psychiatry Advisor

Memory-Enhancing Supplements: What’s the Evidence? Psychiatry Advisor

Protein ontology on the semantic web for knowledge discovery - Nature

Protein ontology on the semantic web for knowledge discovery Nature

Tau PET Tracers Expanding Alzheimer’s and Frontotemporal Dementia Research - Imaging Technology News

Tau PET Tracers Expanding Alzheimer’s and Frontotemporal Dementia Research Imaging Technology News

What is Wrong with the Neuroscience Drug Market? - PharmTech

What is Wrong with the Neuroscience Drug Market? PharmTech

SfN journal retracts paper, bans UPenn researchers over “data misrepresentation” - Retraction Watch

SfN journal retracts paper, bans UPenn researchers over “data misrepresentation” Retraction Watch

(PDF) A Genome-wide Gene-Expression Analysis and Database in Transgenic Mice during Development of Amyloid or Tau Pathology - researchgate.net

(PDF) A Genome-wide Gene-Expression Analysis and Database in Transgenic Mice during Development of Amyloid or Tau Pathology researchgate.net

Plaques in Brains of Alzheimer's Patients May Originate Inside the Nerve Cells, Not Outside, Research Shows - WCM Newsroom

Plaques in Brains of Alzheimer's Patients May Originate Inside the Nerve Cells, Not Outside, Research Shows WCM Newsroom

Top Alzforum Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant